Migraine Linked to Increased Risk of IBD in New Study

Health & Lifestyle
280

Listen to article (english)

Translate to Spanish or other 102 languages!

Could migraine increase the risk of inflammatory bowel disease? A new study found a link. Image for illustration purposes
Could migraine increase the risk of inflammatory bowel disease? A new study found a link. Image for illustration purposes

Medical News Today

- Advertisement -
  • More than 1 billion people around the world have at least one migraine attack each year. 
  • Previous research shows that migraine can potentially increase a person’s risk for several health issues, including gastrointestinal conditions.
  • New research from Seoul National University College of Medicine in South Korea says there may also be a link between migraine and an increased risk for inflammatory bowel disease (IBD). 

More than 1 billion peopleTrusted Source globally have at least one migraine attack each year. 

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/migraine-increased-risk-of-ibd-inflammatory-bowel-disease-study?utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2024-01-23&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
What Hispanic People – & Everyone – Should Know About Clinical Trials
Next article
Caffeine Consumption: Some Sources May Surprise You

More Articles

Skin Myths Dermatologists Want You to Stop Believing Immediately

Have you ever wondered what a dermatologist's top skincare recommendations are

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Practical Health Tips to Navigate Cold and Flu Season Safely

With cold and flu season in full swing, experts say there are some simple steps you can take to protect yourself and those around you.

New Therapy for Head and Neck Squamous Cell Carcinoma Receives Accelerated FDA Approval

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.
- Advertisement -